home / stock / avxl / avxl quote
Last: | $3.84 |
---|---|
Change Percent: | -0.52% |
Open: | $3.86 |
Close: | $3.84 |
High: | $3.95 |
Low: | $3.7602 |
Volume: | 876,398 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.84 | $3.86 | $3.84 | $3.95 | $3.7602 | 876,398 | 05-07-2024 |
$3.84 | $3.87 | $3.84 | $3.87 | $3.76 | 672,936 | 05-06-2024 |
$3.85 | $3.89 | $3.85 | $3.98 | $3.82 | 872,311 | 05-03-2024 |
$3.76 | $3.73 | $3.76 | $3.77 | $3.625 | 743,329 | 05-02-2024 |
$3.69 | $3.66 | $3.69 | $3.85 | $3.53 | 1,434,796 | 05-01-2024 |
$3.65 | $3.6 | $3.65 | $3.745 | $3.54 | 882,438 | 04-30-2024 |
$3.65 | $3.42 | $3.65 | $3.745 | $3.41 | 1,161,530 | 04-29-2024 |
$3.44 | $3.4 | $3.44 | $3.48 | $3.37 | 949,972 | 04-26-2024 |
$3.39 | $3.38 | $3.39 | $3.465 | $3.25 | 1,272,866 | 04-25-2024 |
$3.41 | $3.71 | $3.41 | $3.8 | $3.39 | 1,950,026 | 04-24-2024 |
$3.68 | $3.69 | $3.68 | $3.91 | $3.67 | 1,359,315 | 04-23-2024 |
$3.68 | $3.85 | $3.68 | $3.85 | $3.64 | 1,358,524 | 04-22-2024 |
$3.78 | $3.76 | $3.78 | $3.8 | $3.6 | 2,084,019 | 04-19-2024 |
$3.8 | $4.05 | $3.8 | $4.08 | $3.79 | 1,659,800 | 04-18-2024 |
$4.07 | $4.2 | $4.07 | $4.2005 | $4.02 | 1,337,487 | 04-17-2024 |
$4.12 | $4.15 | $4.12 | $4.19 | $4.06 | 1,252,081 | 04-16-2024 |
$4.23 | $4.31 | $4.23 | $4.3644 | $4.175 | 1,089,915 | 04-15-2024 |
$4.295 | $4.41 | $4.295 | $4.4662 | $4.16 | 1,127,643 | 04-12-2024 |
$4.45 | $4.3 | $4.45 | $4.5 | $4.3 | 803,845 | 04-11-2024 |
$4.29 | $4.23 | $4.29 | $4.295 | $4.17 | 1,411,559 | 04-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
LOS ANGELES, May 07, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class a...
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders i...
LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...